Cetirizine

Generic Name: Cetirizine

Brand Names: Aller-tec, Aller-tec D, Quzyttir, Reactine, Wal Zyr 24 Hour Allergy, Wal Zyr D, Wal-zyr, Zerviate, Zyrtec, Zyrtec-D

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₅ClN_₂O_₃

CAS Number: 83881-51-0

Unique Ingredient Identifier: YO7261ME24

Background: Cetirizine, also commonly known as Zyrtec, is an orally active second-generation histamine H1 antagonist proven effective in the treatment of various allergic symptoms, such as sneezing, coughing, nasal congestion, hives, and other symptoms , .
...

Indication: Seasonal Allergic Rhinitis: Indicated for the relief of symptoms associated with seasonal allergic rhinitis caused by allergens such as ragweed, grass and tree pollens in adults and children 2 years of age and above. Symptoms treated effectively include sneezing, rhinorrhea, nasal pruritus, ocular pruritus, tearing, and redness of the eyes .
...

Associated Conditions: Allergy to Tree Pollen, Chronic Idiopathic Urticaria, Flu caused by Influenza, Perennial Allergic Rhinitis (PAR), Respiratory Allergy, Seasonal Allergic Rhinitis

Associated Therapies: -

Clinical Trials

Comparability and Standardization of Controlled Allergen Challenge Facilities

Phase 4

Completed

Conditions: Allergic Rhinitis

Interventions: Other: Placebo
Drug: Cetirizine

First Posted Date: 2015-09-07

Last Posted Date: 2019-04-09

Lead Sponsor: Queen's University

Target Recruit Count: 98

Registration Number: NCT02543346

Locations: 🇺🇸
Biogenics Research Chamber, San Antonio, Texas, United States
🇨🇦
Kingston General Hospital, Kingston, Ontario, Canada

A Study of ARC-520 at Varying Infusion Rates in Healthy Adult Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: ARC-520
Drug: diphenhydramine
Drug: cetirizine

First Posted Date: 2015-08-28

Last Posted Date: 2018-02-26

Lead Sponsor: Arrowhead Pharmaceuticals

Target Recruit Count: 40

Registration Number: NCT02535416

Locations: 🇦🇺
QPharm, Pty Limited, Royal Brisbane Hospital, Herston, Queensland, Australia

Phase 1 Study of Levocetirizine

Phase 1

Completed

Conditions: Dermatitis

Interventions: Drug: cetirizine
Drug: placebo
Drug: levocetirizine

First Posted Date: 2015-05-18

Last Posted Date: 2017-08-03

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 20

Registration Number: NCT02447393

Locations: 🇯🇵
GSK Investigational Site, Kagoshima, Japan

Management Of The Infusion-Associated Reactions In RRMS Patients Treated With LEMTRADA

Phase 4

Completed

Conditions: Relapsing-remitting Multiple Sclerosis

Interventions: Drug: Alemtuzumab GZ402673
Drug: cetirizine
Drug: ranitidine
Drug: methylprednisolone
Drug: aciclovir
Drug: esomeprazole
Drug: ibuprofen
Drug: paracetamol

First Posted Date: 2014-07-31

Last Posted Date: 2016-06-09

Lead Sponsor: Genzyme, a Sanofi Company

Target Recruit Count: 58

Registration Number: NCT02205489

Locations: 🇧🇪
Investigational Site Number 056001, Brussels, Belgium
🇳🇱
Investigational Site Number 528001, Breda, Netherlands
🇳🇱
Investigational Site Number 528002, Rotterdam, Netherlands

and more 17 locations

Anti-histamines and Methacholine Challenges.

Phase 4

Completed

Conditions: Asthma

Interventions: Drug: placebo
Drug: Diphenhydramine
Drug: cetirizine
Drug: desloratadine

First Posted Date: 2013-11-15

Last Posted Date: 2015-04-08

Lead Sponsor: Don Cockcroft

Target Recruit Count: 12

Registration Number: NCT01985789

Locations: 🇨🇦
University of Saskatchewan, Saskatoon, Saskatchewan, Canada

Evaluation of the Inhibitory Effect of 5 Anti-Histamines in Urticaria

Phase 4

Completed

Conditions: Urticaria

Interventions: Drug: Ebastine
Drug: Cetirizine
Drug: Desloratadine
Drug: Fexofenadine
Drug: Bilastine

First Posted Date: 2013-09-12

Last Posted Date: 2014-02-19

Lead Sponsor: Grupo de Alergología Clínica y Experimental

Target Recruit Count: 150

Registration Number: NCT01940393

Locations: 🇨🇴
Medellin, Medellin, Antioquia, Colombia

A Comparator Study of Fluticasone Propionate Nasal Spray Verses (vs) Cetirizine in the Treatment of Seasonal Allergic Rhinitis

Phase 4

Completed

Conditions: Rhinitis, Allergic, Perennial and Seasonal

Interventions: Drug: Cetirizine Placebo
Drug: FPNS
Drug: FPNS Placebo
Drug: Cetirizine

First Posted Date: 2013-08-05

Last Posted Date: 2018-06-20

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 682

Registration Number: NCT01916226

Locations: 🇺🇸
GSK Investigational Site, Greenfield, Wisconsin, United States

Study of Using Long Acting Antihistamine to Treat Opioid Induced Itching

Phase 4

Terminated

Conditions: Pruritus

Interventions: Drug: Placebo or sugar pill
Drug: Cetirizine

First Posted Date: 2013-04-05

Last Posted Date: 2018-10-10

Lead Sponsor: Virginia Commonwealth University

Target Recruit Count: 3

Registration Number: NCT01825655

Locations: 🇺🇸
Children's Hospital of Richmond at VCU, Richmond, Virginia, United States

Study of Bronchodilation Effects of Cetirizine

Phase 4

Completed

Conditions: Allergic Rhinitis
Asthma

Interventions: Drug: Placebo
Drug: Cetirizine

First Posted Date: 2013-02-01

Last Posted Date: 2013-09-04

Lead Sponsor: California Allergy and Asthma Medical Group, Inc.

Target Recruit Count: 21

Registration Number: NCT01781507

Locations: 🇺🇸
California Allergy and Asthma Medical Group, Los Angeles, California, United States

Phase II Study Evaluating ONO-4053 and Cetirizine in Subjects With Seasonal Allergic Rhinitis

Phase 2

Completed

Conditions: Seasonal Allergic Rhinitis

Interventions: Drug: High dose ONO-4053
Drug: Low dose ONO-4053
Drug: Placebo
Drug: Cetirizine

First Posted Date: 2012-12-12

Last Posted Date: 2014-04-15

Lead Sponsor: Ono Pharmaceutical Co. Ltd

Target Recruit Count: 58

Registration Number: NCT01748344

Locations: 🇦🇹
Vienna Clinical Site, Vienna, Austria

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy